HC Wainwright Reiterates “Buy” Rating for XOMA Royalty (NASDAQ:XOMA)

XOMA Royalty (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $97.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 237.86% from the stock’s current price.

Other analysts have also recently issued reports about the stock. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a research note on Friday, December 12th. UBS Group set a $76.00 price objective on XOMA Royalty in a research report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, XOMA Royalty presently has an average rating of “Hold” and an average price target of $61.60.

XOMA Royalty Trading Down 0.2%

Shares of XOMA opened at $28.71 on Friday. The company’s fifty day moving average is $26.09 and its 200 day moving average is $30.43. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $39.92. The stock has a market capitalization of $341.82 million, a PE ratio of 19.66 and a beta of 0.86. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.91 and a current ratio of 3.37.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. The business had revenue of $13.76 million during the quarter, compared to analyst estimates of $11.13 million. Sell-side analysts expect that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

Several institutional investors have recently made changes to their positions in XOMA. State of Alaska Department of Revenue purchased a new position in shares of XOMA Royalty during the 4th quarter worth about $27,000. Russell Investments Group Ltd. raised its position in XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares during the period. Tower Research Capital LLC TRC lifted its stake in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of XOMA Royalty during the second quarter valued at approximately $116,000. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.